
BTTAY
US listing · $1.60B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 28, 2025 | Time not confirmed | — | -0.05 | — |
| Nov 14, 2024 | Time not confirmed | — | -0.13 | — |
| Aug 6, 2024 | Time not confirmed | — | 0.13 | — |
| May 7, 2024 | Time not confirmed | — | 0.40 | — |
| Mar 28, 2024 | Time not confirmed | — | 0.52 | — |
| Nov 2, 2023 | Time not confirmed | — | 1.19 | — |
| Aug 10, 2023 | Time not confirmed | — | 0.31 | — |
| May 9, 2023 | Time not confirmed | — | -0.28 | — |
| Mar 23, 2023 | Time not confirmed | — | 0.03 | — |
| Nov 14, 2022 | Time not confirmed | — | -0.18 | — |
| Aug 11, 2022 | Time not confirmed | — | -0.20 | — |
| May 5, 2022 | Time not confirmed | — | -0.07 | — |
| Mar 24, 2022 | Time not confirmed | — | -0.51 | — |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B…